Research ArticleCancer

Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer

See allHide authors and affiliations

Science Translational Medicine  04 Dec 2019:
Vol. 11, Issue 521, eaax0428
DOI: 10.1126/scitranslmed.aax0428

Article Information

vol. 11 no. 521

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication February 17, 2019
  • Resubmitted June 11, 2019
  • Accepted for publication October 3, 2019
  • .

Author Information

  1. Yanjing Li1,
  2. Yiping He1,
  3. William Butler1,
  4. Lingfan Xu1,2,
  5. Yan Chang1,3,
  6. Kefeng Lei1,4,
  7. Hong Zhang1,
  8. Yinglu Zhou1,
  9. Allen C. Gao5,
  10. Qingfu Zhang1,6,
  11. Daniel G. Taylor7,
  12. Donghui Cheng8,
  13. Suzette Farber-Katz9,
  14. Rachid Karam9,
  15. Tyler Landrith9,
  16. Bing Li9,
  17. Sitao Wu9,
  18. Vickie Hsuan9,
  19. Qing Yang10,
  20. Hailiang Hu1,
  21. Xufeng Chen1,
  22. Melissa Flowers1,
  23. Shannon J. McCall1,
  24. John K. Lee11,12,
  25. Bryan A. Smith8,
  26. Jung Wook Park8,
  27. Andrew S. Goldstein7,13,14,
  28. Owen N. Witte8,13,15,
  29. Qianben Wang1,
  30. Matthew B. Rettig11,14,16,
  31. Andrew J. Armstrong17,
  32. Qing Cheng18,* and
  33. Jiaoti Huang1,*
  1. 1Department of Pathology, Duke University School of Medicine, Durham, NC 27710, USA.
  2. 2Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China.
  3. 3Department of Pharmacology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China.
  4. 4General Surgery, Zhejiang Provincial People’s Hospital, Hangzhou Medical College, Zhejiang 310014, China.
  5. 5Department of Urology and Cancer Center, University of California Davis School of Medicine, Sacramento, CA 95616, USA.
  6. 6Department of Pathology, The First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang 110122, China.
  7. 7Department of Molecular, Cellular, Developmental Biology, University of California, Los Angeles, CA 90095, USA.
  8. 8Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
  9. 9Ambry Genetics, Aliso Viejo, CA 92656, USA.
  10. 10School of Nursing, Duke University, Durham, NC 27710, USA.
  11. 11Division of Hematology-Oncology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
  12. 12Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA.
  13. 13Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA.
  14. 14Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
  15. 15Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
  16. 16VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA.
  17. 17Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, USA.
  18. 18Department of Surgery, Duke University School of Medicine, Durham NC27710, USA.
  1. *Corresponding author. Email: jiaoti.huang{at}duke.edu (J.H.); q.cheng{at}duke.edu (Q.C.)

Altmetric

Article usage

Article usage: December 2019 to February 2021

AbstractFullPdf
Dec 201975251420753
Jan 20201921198134
Feb 2020168812195
Mar 20208387055
Apr 20201534044
May 20201805558
Jun 20201336337
Jul 20201005536
Aug 2020764223
Sep 20201165831
Oct 20201016820
Nov 20201366655
Dec 20202321988
Jan 2021623958
Feb 2021111047

Stay Connected to Science Translational Medicine

Navigate This Article